Clinical Trial Update: R-MTX-zanbrutinib in Secondary CNS Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for R-MTX-zanbrutinib in Secondary Central Nervous System Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• R-MTX-zanbrutinib

Snippet

Sponsor: Peking University | Conditions: Secondary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN